The private sector, short of funding, is finding NIH a useful source of support. As large-scale biomedical research becomes prevalent and as industry's early-stage R&D productivity falters, both parties have an interest in collaborating more than in the past. But in general, NIH isn't set up to manage the transformation of so many promising discoveries into clinically useful products. It's determined to change that situation with the introduction in October of this year of a "roadmap" for collaborations of many kinds. Even before this event, however, NCI, the largest institute within NIH, had undertaken several public-private programs to expedite development of new products. The institute's experiences illustrate some of advantages and pitfalls of public-private initiatives.
By Wendy Diller
National Institutes of Health (NIH) Director Elias Zerhouni, MD's announcement in early October 2003 of a new "roadmap" for...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.
Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
Multi-blockbuster falls short in a giant cell arteritis study.
